M. Haenel

发表

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2019, The Lancet.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT

J. Esteve, R. Foà, M. Labopin, 2018, Blood.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2018, British journal of haematology.

Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)

W. Hiddemann, M. Dreyling, M. Gramatzki, 2005 .

Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)

W. Hiddemann, R. Parwaresch, W. Ludwig, 2005 .

CNS Disease In Younger Patients (

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2010 .

Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2014 .

Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2008 .

Dose-Dense Rituximab Improves Outcome of Elderly Patients with Poor-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2007 .

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies

G. Ehninger, T. Illmer, U. Schuler, 2002, Intensive Care Medicine.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

A. Rosenwald, M. Ziepert, N. Schmitz, 2012, The Lancet. Oncology.

CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study.

E. Thiel, U. Schlegel, P. Martus, 2012 .

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

A. Rosenwald, M. Ziepert, N. Schmitz, 2021, The Lancet. Haematology.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Leukemia.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

H. Einsele, T. Brümmendorf, A. Krämer, 2020, Blood.

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

D. Niederwieser, M. Cross, H. Al-Ali, 2017 .

Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1 -Mutations and High or Low Ratio FLT3-ITD s

N. Schmitz, H. Einsele, W. Berdel, 2017 .

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2010 .

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, SSRN Electronic Journal.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

A. Rosenwald, M. Ziepert, N. Schmitz, 2020, Blood.

Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2017 .

Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2018 .

Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2017 .

Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas

G. Ehninger, R. Prondzinsky, M. Haenel, 2008, Cancer Chemotherapy and Pharmacology.

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

H. Goldschmidt, A. Jauch, T. Hielscher, 2018, Blood.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

deletion 17p transplantation improves outcome in multiple myeloma patients with Administration of bortezomib before and after autologous stem cell

D. Hose, H. Goldschmidt, A. Jauch, 2012 .

Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

H. Goldschmidt, A. Ho, I. Schmidt-Wolf, 2017, European journal of haematology.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients wi

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

S. Montoto, H. Goldschmidt, H. Einsele, 2016 .

Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia

C. Eberlein, N. Schmitz, H. Einsele, 2016 .

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.